SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

*(Incorporated in the Cayman Islands with limited liability)*
*Website: www.sinobiopharm.com*
**(Stock code: 1177)**

# VOLUNTARY ANNOUNCEMENT
# APPLICATION FOR PHASE IB/II CLINICAL TRIAL OF INNOVATIVE DRUG "GMA106 (GIPR ANTAGONIST/GLP-1R AGONIST)" ACCEPTED BY CDE

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that application for Phase Ib/II clinical trial of "GMA106 (GIPR antagonist/GLP-1R agonist)", a Category 1 innovative drug co-developed by the Group for the treatment of adult overweight and obese patients, has been submitted to and accepted by the Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration of the People's Republic of China.

GMA106 is a GIPR (gastric inhibitory peptide receptor) antagonist/GLP-1R (glucagon-like peptide-1 receptor) agonist, which, by utilizing the proprietary M-Body technology, can specifically block the GIPR signaling pathway while simultaneously activate GLP-1R, resulting in the following effects:

1. Notable weight loss effect: Reduces body fat accumulation, slows gastric emptying, suppresses appetite, and achieves better weight loss effect than single GLP-1 receptor agonist through multi-pathway synergism;

2. Good safety: Preliminary data of Phase I clinical trial conducted in Australia showed good tolerability and safety;

3. Prevention of rebound: Unblinded preliminary efficacy data showed that GMA106 still has the potential to prevent weight rebound 3-5 months after stopping the drug administration; and

4. High compliance: The long half-life of the molecule is expected to result in dosing frequency of one dose every 2 weeks or every 4 weeks, which improves drug compliance of long-term dosing.

Phase I clinical trial of GMA106 has been launched in Australia in November 2021. In China, it is planned to further confirm the safety and tolerability of higher dosing of GMA106 in overweight and obese populations through a Phase Ib study. The Phase II study will explore preliminary efficacy in different cohorts after 24 and 36 weeks of treatment at different doses and dosing frequencies over a long cycle.

China's obese population is nearly 90 million, ranking the highest in the world[1)], and the rate of overweight or obesity among adults has exceeded 50%[2)]. Obesity is a major risk factor for non-communicable diseases, such as cardiovascular diseases, diabetes, musculoskeletal diseases, etc., and can even increase the risk of some cancers[3)], so there is an urgent need for breakthrough therapeutic means to solve the current increasingly prominent problem of overweight and obesity. GMA106 is expected to become a new generation of preferred weight-loss drug candidate for weight reduction, fat loss, and anti-rebound after discontinuation of drug treatment, helping to focus on and solve the imminent health problem of the general public, and offer better choices for long-term health management.

*References:*


1) *https://ncncd.chinacdc.cn/hyxw2/202009/t20200921_220735.htm*
2) *https://m.21jingji.com/article/20220511/herald/0ff2dba96257c362a46bbc9dbb22e15e_zaker.html* (The Chinese Dietary Guidelines (2022))
3) *https://www.who.int/zh/news-room/fact-sheets/detail/obesity-and-overweight*


By order of the Board
**Sino Biopharmaceutical Limited**
**Tse, Theresa Y Y**
*Chairwoman*

Hong Kong, 16 October 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*